Associated Papers
MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.
Park J et al.
Targeted Oncology, 2025
A comprehensive database for identifying and interpreting ctDNA driver genes and variants in cancer.
Wang Y et al.
Scientific Data, 2025
Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.
Feng H et al.
Cancer Biology & Medicine, 2025
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Advances in clinical research of MET exon 14 skipping mutations in non-small cell lung cancer.
Wang M et al.
Journal of Cancer Research and Clinical Oncology, 2025
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors.
Pecci F et al.
Cancer Discovery, 2024
MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report.
Choi W et al.
Translational Lung Cancer Research, 2022
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T et al.
Journal of Hematology & Oncology, 2022
Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib.
Lim SM et al.
Jto Clinical and Research Reports, 2021
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.
Fujino T et al.
Lung Cancer (auckland, N.z.), 2021
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation.
Cai B et al.
Frontiers in Oncology, 2021
Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer.
Piper-Vallillo AJ et al.
Jto Clinical and Research Reports, 2020
[Chinese Expert Consensus on Next Generation Sequencing Diagnosis for Non-small Cell Lung Cancer (2020 Edition)].
Unknown Author
Zhongguo Fei Ai Za Zhi = Chinese Journal of Lung Cancer, 2020
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK et al.
The New England Journal of Medicine, 2020
Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C et al.
Current Treatment Options in Oncology, 2020
Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2020